Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 6/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 6/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 11/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3577762 | 0.92 | RXRA (0.46) | RXRANR1H2NR1H3HSD11B1PTGS2 | |
| SCHEMBL3587406 | 0.90 | PTGS2 (0.47) | RXRANR1H2NR1H3HSD11B1PTGS2 | |
| SCHEMBL3583822 | 0.90 | RXRA (0.46) | RXRANR1H2NR1H3HSD11B1PTGS2 | |
| SCHEMBL3579162 | 0.88 | RXRA (0.51) | RXRANR1H2NR1H3HSD11B1PTGS2 | |
| SCHEMBL3583896 | 0.87 | RXRA (0.56) | RXRANR1H2NR1H3HSD11B1PTGS2 | |
| SCHEMBL3584288 | 0.87 | RXRA (0.51) | RXRANR1H2NR1H3HSD11B1PTGS2 | |
| SCHEMBL3583267 | 0.87 | PTGS2 (0.51) | RXRANR1H2NR1H3HSD11B1PTGS2 | |
| SCHEMBL3579541 | 0.86 | RXRA (0.48) | RXRANR1H2NR1H3HSD11B1PTGS2 | |
| SCHEMBL14621213 | 0.86 | RXRA (0.52) | RXRANR1H2NR1H3HSD11B1PTGS2 | |
| SCHEMBL3583300 | 0.85 | RXRA (0.46) | RXRANR1H2NR1H3HSD11B1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910308-B1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS PATENT CO LLC (US) | 2014-09-03 | — | — | EP | claimed |
| US-8569352-B2 | Imidazole based LXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2013-10-29 | — | — | US | claimed |
| US-9000022-B2 | Imidazole based LXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2015-04-07 | — | — | US | disclosed |
| US-9000022-B2 | Imidazole based LXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2015-04-07 | — | — | US | disclosed |
| US-9000022-B2 | Imidazole based LXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2015-04-07 | — | — | US | disclosed |
| EP-1910308-B1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS PATENT CO LLC (US) | 2014-09-03 | — | — | EP | disclosed |
| US-20140038964-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140038964-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140038964-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2014-02-06 | — | — | US | disclosed |
| US-8569352-B2 | Imidazole based LXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569352-B2 | Imidazole based LXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569352-B2 | Imidazole based LXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2013-10-29 | — | — | US | disclosed |
| US-20100075964-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075964-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075964-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038964-A1 | IMIDAZOLE BASED LXR MODULATORS | NR1H2, NR1H3, NR1H4 | RXRA 17/4885NR1H2 1/4885NR1H3 2/4885 |
| US-20100075964-A1 | IMIDAZOLE BASED LXR MODULATORS | NR1H2, NR1H3, NR1I2 | RXRA 17/4885NR1H2 1/4885NR1H3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.